Transferability of economic evaluations: approaches and factors to consider when using results from one geographic area for another

References

• O’Brien BJ. A tale of two (or more) cities: geographic transferability of pharmacoeconomic data. Am J Managed Care 1997;3:33–9
   Web of Science ®Google Scholar
• Bryan S, Brown J. Extrapolation of cost-effectiveness information to local settings. J Health Serv Res Policy 1998;3:108–12
   PubMedGoogle Scholar
• Drummond MF, O’Brien B, Stoddart G, et al. Methods for the economic evaluation of health care programmes, 2nd ed. New York: Oxford University Press; 1997
   Google Scholar
• Shah A, Jenkins R. Mental health economic studies from developing countries reviewed in the context of those from developed countries. Acta Psychiatr Scand 2000;101:87–103
   PubMed Web of Science ®Google Scholar
• Greiner W, Schoffski O, Graf VDS. The transferability of international economic health-economic results to national study questions. Health Econ Prevention Care 2000;1:94–102
   Google Scholar
• Koopmanschap MA, Touw KC, Rutten FF. Analysis of costs and cost-effectiveness in multinational trials. Health Policy 2001;58:175–86
   Google Scholar
• Drummond M, Pang F. Transferability of economic evaluation results. In: Drummond MF, McGuire A, editors. Economic evaluation in health care: merging theory with practice. New York (NY): Oxford University Press; 2001. p. 256–76
   Google Scholar
• Welte R, Feenstra T, Jager H, et al. A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics 2004;22:857–76
   PubMed Web of Science ®Google Scholar
• Sculpher MJ, Pang FS, Manca A, et al. Generalisability in economic evaluation studies in healthcare: a review and case studies. Health Technol Assess (Winchester, England) 2004;8:1–192
   Web of Science ®Google Scholar
• Tsuchiya A, Ikeda S, Ikegami N, et al. Estimating an EQ-5D population value set: the case of Japan. Health Econ 2002;11:341–53
   PubMed Web of Science ®Google Scholar
• Gosden TB, Torgerson DJ. Economics notes: converting international cost effectiveness data to UK prices [see comment]. Br Med J 2002;325:275–6
   PubMed Web of Science ®Google Scholar
• Gray A. Are the results of cost-effectiveness studies internationally transferable? Paper presented at Health Economists’ Study Group, University of Aberdeen 1991
   Google Scholar
• Wordsworth S, Ludbrook A. Comparing costing results in across country economic evaluations: the use of technology specific purchasing power parities. Health Econ 2005;14:93–9
   PubMed Web of Science ®Google Scholar
• Pang F. Design, analysis and presentation of multinational economic studies: the need for guidance. Pharmacoeconomics 2002;20:75–90
   PubMed Web of Science ®Google Scholar
• Goodman CA, Mills AJ. The evidence base on the cost-effectiveness of malaria control measures in Africa. Health Policy Plann 1999;14:301–12
   PubMed Web of Science ®Google Scholar
• Tonkin AM. Issues in extrapolating from clinical trials to clinical practice and outcomes. Aust New Zealand J Med 1998;28: 574–8
   PubMedGoogle Scholar
• Drummond MF. The future of pharmacoeconomics: bridging science and practice. Clin Ther 1996;18:969–78
   PubMed Web of Science ®Google Scholar
• Baltussen R, Leidl R, Ament A. The impact of age on cost-effectiveness ratios and its control in decision making. Health Econ 1996;5:227–39
   Google Scholar
• Baltussen R, Ament A, Leidl R. Making cost assessments based on RCTs more useful to decision-makers. Health Policy 1996;37:163–83
   Google Scholar
• Glasser JH, Chrzanowski RS. Medical technology assessment: adequate questions, appropriate methods, valuable answers. Health Policy 1988;9:267–76
   PubMed Web of Science ®Google Scholar
• Revicki DA, Frank L. Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies. Pharmacoeconomics 1999;15:423–34
   PubMed Web of Science ®Google Scholar
• Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ 1994;3:95–104
   Google Scholar
• O’Brien BJ. Willingness-to-pay in cost-benefit analysis of health care programs. In: Armitage PC, editors. Encyclopedia of biostatistics [6-Volume Set]; 1998
   Google Scholar
• Drummond MF. Comparing cost effectiveness across countries: the model of acid-related disease. Pharmacoeconomics 1994;5:60–7
   Google Scholar
• Baker AM, Goldberg Arnold RJ, Kaniecki DJ. Considerations in measuring resource use in clinical trials. Drug Inf J 1995;29: 1421–8
   Google Scholar
• Stason WB. Cost-effectiveness analysis in health care: opportunities and challenges to international comparisons. In: Lasser U, Roccella EJ, Rosenfeld JB, Wenzel A, editors. Costs and benefits in health care and prevention: an international approach to priorities in medicine. Berlin: Springer-Verlag; 1990. p. 20–6
   Google Scholar
• Sanchez LA. Applied pharmacoeconomics: evaluation and use of pharmacoeconomic data from the literature. Am J Health-Syst Pharm 1999;56:1630–8
   PubMed Web of Science ®Google Scholar
• Sanchez LA. How to evaluate and interpret outcome studies. Pharmacotherapy 2000;20:282–91
   Web of Science ®Google Scholar
• Raisch DW, Netravali SS, Harris CL. Pharmacoeconomic implications of large multicenter clinical trials. Ann Pharmacother 2003;37:447–50
   Google Scholar
• Grover SA, Coupal L, Zowall H, et al. How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? Diabetes Care 2001;24:45–50
   PubMed Web of Science ®Google Scholar
• Caro J, Klittich W, McGuire A, et al. International economic analysis of primary prevention of cardiovascular disease with pravastatin in WOSCOPS: West Scotland Coronary Prevention Study. Eur Heart J 1999;20:263–8
   PubMed Web of Science ®Google Scholar
• Lord J, Thomason MJ, Littlejohns P, et al. Secondary analysis of economic data: a review of cost-benefit studies of neonatal screening for phenylketonuria. J Epidemiol Community Health 1999;53:179–86
   PubMed Web of Science ®Google Scholar
• Lorenzoni R, Pagano D, Mazzotta G, et al. Pitfalls in the economic evaluation of thrombosis in myocardial infarction. The impact of national differences in the cost of thrombolitics and of differences in the efficacy across patient subgroups. Eur Heart J 1998;19:1518–24
   Google Scholar
• Subramanian S, Liu CF, Cromwell J, et al. Preoperative correlates of the cost of coronary artery bypass graft surgery: comparison of results from three hospitals. Am J Med Quality 2001;16:87–92
   PubMed Web of Science ®Google Scholar
• Attinger EO, Panerai RB. Transferability of health technology assessment with particular emphasis on developing countries. Int J Technol Assess Health Care 1988;4:545–54
   Google Scholar
• Mills A. Operational research on the economics of insecticide treated mosquito nets: lessons of experience. Ann Trop Med Parasitol 1998;92:435–47
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Liljas B, Buxton M, et al. Design and analytic considerations in determining the cost-effectiveness of early intervention in asthma from a multinational clinical trial. Control Clin Trials 2001;22:420–37
   PubMedGoogle Scholar
• Bonsel GJ, Rutten FF, Uyl-de Groot CA. Economic evaluation alongside cancer trials: methodological and practical aspects. Eur J Cancer 1993;29A:10–4
   Google Scholar
• Neymark N, Kiebert W, Torfs K, et al. Methodological and statistical issues of quality of life (QoL) and economic evaluation in cancer clinical trials: report of a workshop. Eur J Cancer 1998;34:1317–33
   PubMed Web of Science ®Google Scholar
• Coyle D, Davies L, Drummond MF. Trials and tribulations. Emerging issues in designing economic evaluations alongside clinical trials. Int J Technol Assess Health Care 1998;14: 135–44
   Google Scholar
• Rizzo JD, Powe NR. Methodological hurdles in conducting pharmacoeconomic analyses. Pharmacoeconomics 1999;15: 339–55
   PubMed Web of Science ®Google Scholar
• Tolley K, Gyldmark M. The treatment and care costs of people with HIV infection or AIDS: development of a standardised cost framework for Europe [Review] [21 refs]. Health Policy 1993;24:55–70
   PubMed Web of Science ®Google Scholar
• Reed SD, Anstrom KJ, Bakhai A, et al. Conducting economic evaluations alongside multinational clinical trials. Am Heart J 2005;149:434–43
   PubMed Web of Science ®Google Scholar
• Fayers PM, Hand DJ. Generalisation from phase III clinical trials: survival, quality of life, and health economics. Lancet 1997;350:1025–7
   PubMed Web of Science ®Google Scholar
• Birch S, Gafni A. Economics and the evaluation of health care programmes: generalisability of methods and implications for generalisability of results. Health Policy 2003;64:207–19
   PubMed Web of Science ®Google Scholar
• Drummond M, Manca A, Sculpher M. Increasing the general-izability of economic evaluations: recommendations for the design, analysis and reporting of studies. Int J Technol Assess Health Care 2005;21:165–71
   Google Scholar
• Drummond M, Sculpher M. Common methodological flaws in economic evaluations. Med Care 2005;43:5–14
   PubMed Web of Science ®Google Scholar
• Mason J. The generalisability of pharmacoeconomic studies. Pharmacoeconomics 1997;11:503–14
   PubMed Web of Science ®Google Scholar
• van Ineveld BM, van Oortmarssen GJ, De Koning HJ, et al. How cost-effective is breast cancer screening in different EC countries? Eur J Cancer 1993;29A:1663–8
   PubMed Web of Science ®Google Scholar
• Ament A, Baltussen R, Duru G, et al. Cost-effectiveness of pneumococal vaccination of older people: a study in 5 western European countries. Clin Infect Dis 2000;31:444–50
   PubMed Web of Science ®Google Scholar
• Simpson K, Hatziandreu EJ, Andersson F, et al. Cost-effectiveness of antiviral treatment with zalcitabine plus zidovudine for AIDS patients with CD4+ counts less than 300/microliters in 5 European countries. Pharmacoeconomics 1994;6:553–62
   PubMed Web of Science ®Google Scholar
• Biddle AKS. Modeling the use of triple combination therapy in five countries: Nevirapine, Zidovudine, and Didanosine. Value in Health 2000;3:186–201
   PubMedGoogle Scholar
• Goodacre S, Dixon S. Is a chest pain observation unit likely to be cost-effective at my hospital? Extrapolation of data from a randomized controlled trial. Emerg Med J 2005;22: 418–22
   PubMed Web of Science ®Google Scholar
• O’Brien B. Economic evaluation of pharmaceuticals. Frankenstein’s monster or vampire of trials? Med Care 1996;34:99–108
   Google Scholar
• Brennan A, Akehurst R. Modelling in health economic evaluation. What is its place? What is its value? Pharmacoeconomics 2000;17:445–59
   Google Scholar
• Neymark N, Rosti G. Patient management strategies and transplantation techniques in European stem cell transplantation centres offering breast cancer patients high-dose chemotherapy with peripheral blood stem cell support: a joint report from the EORTC and EBMT. Haematologica 2000;85:733–44
   PubMed Web of Science ®Google Scholar
• Powe NR, Griffiths RI. The clinical-economic trial: promise, problems and challenges. Control Clin Trials 1995;16:377–94
   PubMedGoogle Scholar
• Drummond M, Brandt A, Luce B, et al. Standardizing methodologies for economic evaluation in health care. Practice, problems and potential. Int J Technol Assess Health Care 1993;9:26–36
   Google Scholar
• Cook J, Drummond M, Heyse JF. Economic endpoints in clinical trials. Stat Methods Med Res 2004;13:157–76
   PubMedGoogle Scholar
• O’Brien BJ, Heyland D, Richardson WS, et al. Users’ guides to the medical literature XIII. How to use an article on economic analysis of clinical practice B. What are the results and will they help me in caring for my patients? J Am Med Assoc 1997;277:1802–6
   Google Scholar
• Mugford M, Hutton G, Fox-Rushby J. Methods for economic evaluation alongside a multicentre trial in developing countries: a case study from the WHO antenatal care randomised controlled trial. Paediatr Perinat Epidemiol 1998;12:75–97
   Google Scholar
• Goeree R, Gafni A, Hannah M, et al. Hospital selection for unit cost estimates in multicentre economic evaluations. Does the choice of hospitals make a difference? Pharmacoeconomics 1999;15:561–72
   Google Scholar
• Rutten F. Economic evaluation and health care decision-making. Health Policy 1996;36:215–29
   PubMed Web of Science ®Google Scholar
• Carr-Hill RA. The evaluation of health care. Soc Sci Med 1985;21:367–75
   PubMed Web of Science ®Google Scholar
• Willke RJ. Tailor-made or off-the-rack? The problem of transferability of health economic data. Expert Rev Pharmacoeconomics Outcomes Res 2003;3:1–4
   PubMedGoogle Scholar
• Mason J, Drummond MJ, Torrance G. Some of the guidelines on the use of cost effectiveness league tables. Br Med J 1993;306:570–2
   Google Scholar
• Haycox A, Drummond M, Walley T. Pharmacoeconomics: integrating economic evaluation into clinical trials. Br J Clin Pharmacol 1997;43:559–62
   Google Scholar
• Haycox A, Dubois D, Butterworth M. Customising an international disease management model to the needs of individual countries. Application to upper gastrointestinal disease. Pharmacoeconomics 1998;14:39–56
   Google Scholar
• Schiller J, Tilden D, Aristides M, et al. Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe. Lung Cancer 2004;43:101–12
   PubMed Web of Science ®Google Scholar
• Goodacre S, Morris F, Arnold J, et al. Is a chest pain observation unit likely to be cost saving in a British hospital? Emerg Med J 2001;18:11–4
   PubMed Web of Science ®Google Scholar
• Pinto CG, Lafuma A, Fagnani F, et al. Cost-effectiveness of emedastine versus levocabastine in the treatment of allergic conjunctivitis in 7 European countries. Pharmacoeconomics 2001;19:255–65
   PubMed Web of Science ®Google Scholar
• Lacey L, Mauskopf J, Lindrooth R, et al. A prospective cost-consequence analysis of adding lamivudine to zidovudine-containing antiretroviral treatment regimens for HIV infection in the US. Pharmacoeconomics 1999;15:23–37
   PubMed Web of Science ®Google Scholar
• Berger K, Fischer T, Szucs TD. Cost-effectiveness analysis of paclitaxel and cisplatin versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer. Eur J Cancer 1998;34:1894–901
   Google Scholar
• Jonsson B, Johannesson M, Kjekshus J, et al. Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study. Eur Heart J 1996;17:1001–7
   Google Scholar
• Menzin J, Oster G, Davies L, et al. A multinational economic evaluation of rhDNase in the treatment of cystic fibrosis. Int J Technol Assess Health Care 1996;12:52–61
   PubMed Web of Science ®Google Scholar
• Jonsson B, Cook JR, Pedersen TR. The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial. Diabetologia 1999;42: 1293–301
   Google Scholar
• Jansen RB, Capri S, Nuijten MJC, et al. Economic evaluation of meloxicam (7.5 mg) versus sustained release diclofenac (100 mg) treatment for osteoarthritis: a cross-national assessment for France, Italy and the UK. Br J Med Econ 1997;11: 9–2
   Google Scholar
• Casciano J, Doyle J, Arikian S, et al. The health economic impact of antidepressant usage from a payer’s perspective: a multinational study. Int J Clin Pract 2001;55:292–9
   PubMed Web of Science ®Google Scholar
• Shear NH, Einarson TR, Arikian SR, et al. Pharmacoeconomic analysis of topical treatments for tinea infections. Int J Dermatol 1998;37:64–71
   PubMed Web of Science ®Google Scholar
• Arikian SR, Einarson TR, Kobelt-Nguyen G, et al. A multinational pharmacoeconomic analysis of oral therapies for onychomycosis [The Onychomycosis Study Group]. Br J Dermatol 1994;130:35–44
   Google Scholar
• Einarson TR, Oh PI, Gupta AK, et al. Multinational pharmaco-economic analysis of topical and oral therapies for onychomycosis. J Dermatol Treat 1997;8:235
   Web of Science ®Google Scholar
• Ghatnekar O, Persson U, Willis M, et al. Cost-effectiveness of Becaplermin in the treatment of diabetic food ulcers in four European countries. Pharmacoeconomics 2001;19:767–78
   PubMed Web of Science ®Google Scholar
• Rittenhouse BE. The relevance of searching for effects under a clinical-trial lamppost: a key issue. Med Decis Mak 1995;15: 348–57
   PubMed Web of Science ®Google Scholar
• Bennett CL, Armitage JL, Buchner D, et al. Economic analysis in phase III clinical cancer trials. Cancer Invest 1994;12:336–42
   PubMed Web of Science ®Google Scholar
• Dixon S, Deverill M, Gannon M, et al. Improving the validity of economic evaluations alongside controlled trials. J Health Serv Res Policy 1999;4:161–3
   PubMedGoogle Scholar
• Rittenhouse BE. Another deficit problem: the deficit of relevant information when clinical trials are the basis for pharmaco-economic research. J Res Pharm Econ 1996;7:3–15
   Google Scholar
• Badia X, Russo P, Attanasio E. A comparative economic analysis of simvastatin versus atorvastatin: results of the Surrogate Marker Cost-efficacy (SMaC) study. Clin Ther 1999;21: 1788–96
   Google Scholar
• Hull R, Hirsh J, Sackett DL, et al. Cost effectiveness of clinical diagnosis, venography, and noninvasive testing in patients with symptomatic deep-vein thrombosis. New Engl J Med 1981;304:1561–7
   PubMed Web of Science ®Google Scholar
• Nicholls CJ, Hale AS, Freemantle N. Cost-effectiveness of amisulpride compared with risperidone in patients with schizophrenia. J Med Econ 2003;6:31–41
   Google Scholar
• Palmqvist M, Price MJ, Sondhi S. Cost-effectiveness analysis of salmeterol/fluticasone propionate 50/250 µg vs fluticasone propionate 250 µg in adults and adolescents with asthma IV: results. Pharmacoeconomics 1999;16: 23–8
   Google Scholar
• Pieters WR, Lundback B, Sondhi S, et al. Cost-effectiveness analysis of salmeterol/fluticasone propionate 50/500 µg vs fluticasone propionate 500 µg in patients with corticosteroid-dependent asthma V: results. Pharmacoeconomics 1999; 16:29–34
   Web of Science ®Google Scholar
• Scott WG, Cooper BC, Scott HM, et al. Cost-effectiveness of roxithromycin versus cefaclor in Australia. Pharmacoeconomics 1995;7:93–4
   PubMed Web of Science ®Google Scholar
• Hirsch B, O’Donnell J JP. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, prevastatin and simvastatin: analysis of the STELLAR trial. Eur J Cardiovascular Prevention Rehabilitation 2005;12:18–28
   PubMed Web of Science ®Google Scholar
• Akehurst RL, Backhouse M, Emery P, et al. Nabumetone compared with ibuprofen and a weighted NSAID combination: an economic evaluation. J Med Econ 1998;1:19–37
   Google Scholar
• Iveson TJ, Hickish T, Schmitt C, et al. Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU. Eur J Cancer 1999;35:1796–804
   PubMed Web of Science ®Google Scholar
• Jonsson B, Haglund U. Cost-effectiveness of misoprostol in Sweden. Int J Technol Assess Health Care 1992;8:234–44
   PubMedGoogle Scholar
• LeLorier J, Perreault S, Birnbaum H, et al. Savings in direct medical costs from the use of tobramycin solution for inhalation in patients with cystic fibrosis. Clin Ther 2000;21:140–51
   Google Scholar
• Smith TJ, Hillner BE, Schmitz N, et al. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin’s and non-Hodgkin’s lymphoma. J Clin Oncol 1997;15:5–10
   PubMed Web of Science ®Google Scholar
• Bachynsky J, McCracken P, Lier D, et al. Propentofylline treatment for Alzheimer’s disease and vascular dementia: an economic evaluation based on functional abilities. Alzheimer Dis Assoc Disord 2000;14:102–11
   PubMed Web of Science ®Google Scholar
• Caro JJ, Huybrechts KF, DeBacker G, et al. Are the WOSCOPS clinical and economic findings generalizable to other populations? A case study for Belgium [The WOSCOPS economic analysis Group; West of Scotland Coronary Prevention Study]. Acta Cardiol 2000;55:239–46
   PubMed Web of Science ®Google Scholar
• Ghatnekar O, Willis M, Persson U. Cost-effectiveness of treating deep diabetic foot ulcers with Pomogran in four European countries. J Wound Care 2002;11:70–4
   Google Scholar
• Hart WM, Rovira J. Cost analysis of University of Wisconsin solution versus Euro-Collins solution in the preservation of kidneys for transplantation in Spain. Transplant J Cell Organ Transplant 1995;6:149–52
   Google Scholar
• Hassanein T, Oliver D, Strange J, et al. Albumin dialysis in cirrhosis with superimposed acute liver inquiry: possible impact of albumin dialysis on hospitalization costs. Liver Int 2003;23:61–5
   PubMed Web of Science ®Google Scholar
• Tuil E, Hommer AB, Poulsen PB, et al. The cost-effectiveness of bimatoprost 0.03% in the treatment of glaucoma in adult patients – a European perspective. Int J Clin Pract 2005;59: 1011–6
   Google Scholar